Spots Global Cancer Trial Database for Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
Official Title: Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced Non-small Cell Lung Cancer
Study ID: NCT04322578
Conditions
Interventions
Study Description
Brief Summary: This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer
Detailed Description: This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer . All the clinical and survival data will be collected for full analysis.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Yongchang Zhang, Changsha, Hunan, China
Contact Details
Name: Yongchang Zhang, MD
Affiliation: Hunan Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
